Relevant bibliographies by topics / He52

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'He52'

Author: Grafiati
Published: 28 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'He52.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "He52"

1

Yagisawa, Masataka, Kentaro Sawada, Yoshiaki Nakamura, et al. "Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer." Journal of Clinical Oncology 38, no. 4_suppl (2020): 229. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.229.

Full text
Abstract:
229 Background: HER2 dual blockade showed the promise in clinical trials in patients (pts) with HER2-positive (HER2-Pos) metastatic colorectal cancer (mCRC). A phase I/II study of a novel anti-HER2 antibody-drug conjugate (HER2-ADC) showed promising activities across different cancer subtypes including HER2-Pos mCRC, and also showed a hint of activity for low-expressing (HER2-L) mCRC, regardless of RAS mutation. However, molecular landscape and prognostic value of HER2-L on mCRC are unclear. Methods: The eligibility included pts with mCRC who had undergone surgical resection of primary tumor.
APA, Harvard, Vancouver, ISO, and other styles
2

Suchocki, Tomasz. "Performance and Emission Characteristics of a Small Gas Turbine Engine Using Hexanol as a Biomass-Derived Fuel." Materials 17, no. 23 (2024): 6011. https://doi.org/10.3390/ma17236011.

Full text
Abstract:
The global transition to renewable energy has amplified the need for sustainable aviation fuels. This study investigates hexanol, a biomass-derived alcohol, as an alternative fuel for small-scale gas turbines. Experimental trials were conducted on a JETPOL GTM-160 turbine, assessing blends of 25% (He25) and 50% (He50) hexanol with kerosene (JET A) under rotational velocities ranging from 40,000 to 110,000 RPM. The parameters measured included thrust-specific fuel consumption (TSFC), turbine inlet and outlet velocities, and the emission indices of NOx and CO. The results demonstrated that the H
APA, Harvard, Vancouver, ISO, and other styles
3

Hees, van, Martin. "Vrijheid en verantwoordelijkheid: nawoord." Algemeen Nederlands Tijdschrift voor Wijsbegeerte 105, no. 4 (2013): 257–64. http://dx.doi.org/10.5117/antw2013.4.hee2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hendriks, Petra, and Eric Reuland. "Waar komen de bindingscondities vandaan?" Nederlandse taalkunde 18, no. 2 (2013): 179–86. http://dx.doi.org/10.5117/nedtaa2013.2.hen2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

YENUGU, Suresh, Katherine G. HAMIL, Charles E. BIRSE, Steven M. RUBEN, Frank S. FRENCH, and Susan H. HALL. "Antibacterial properties of the sperm-binding proteins and peptides of human epididymis 2 (HE2) family; salt sensitivity, structural dependence and their interaction with outer and cytoplasmic membranes of Escherichia coli." Biochemical Journal 372, no. 2 (2003): 473–83. http://dx.doi.org/10.1042/bj20030225.

Full text
Abstract:
During passage through the epididymis, sperm interact with secreted epididymal proteins that promote maturation, including the acquisition of motility and fertilization competence. Viewed previously as distinct from sperm maturation, host defence capabilities are now recognized functions of the human epididymis 2 (HE2) family of sperm-binding proteins. We analysed the potent dose and time-dependent bactericidal activity of recombinant HE2α, HE2β1 and HE2β2 and found that the full-length proteins (10 μg/ml or ~1 μM) caused more than a 50% decrease in Escherichia coli colony forming units within
APA, Harvard, Vancouver, ISO, and other styles
6

Prat, A., O. Karginova, C. Fan, and C. M. Perou. "Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes." Journal of Clinical Oncology 27, no. 15_suppl (2009): 11017. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11017.

Full text
Abstract:
11017 Background: An attractive candidate target for breast cancer (BC) and BC tumor-initiating cells is the Notch signaling pathway. To better understand the potential dependence of breast cancer upon Notch-signaling, we used a genomic approach to study the activation of this pathway in the different molecular subtypes. Methods: Breast basal-like, luminal and HER2+ cell lines were examined for sensitivity to gamma-secretase inhibition (GSI). Gene expression data from the most sensitive cell line was analyzed during treatment and upon releasing from GSI (4h, 8h and 24h post-treatment). Using a
APA, Harvard, Vancouver, ISO, and other styles
7

Fang, Yutong, Qunchen Zhang, Yuan Wu, and Jundong Wu. "HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer." Medicine 103, no. 6 (2024): e37170. http://dx.doi.org/10.1097/md.0000000000037170.

Full text
Abstract:
The growing body of evidence suggests that breast cancer (BC) who achieve pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) may experience a more favorable prognosis. The objective of this study is to investigate the correlation between clinicopathologic parameters of locally advanced breast cancer (LABC) patients and the outcomes of NAC, with the aim of identifying predictive indicators for pCR. Additionally, we seek to examine the conversion of IHC markers in pCR patients following NAC and its impact on the prognosis of BC patients. We conducted a study involving 126
APA, Harvard, Vancouver, ISO, and other styles
8

Zhukova, L. G. Zhukova, E. V. Artamonova Artamonova, I. P. Ganshina Ganshina, et al. "Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer." Pharmateca 11_2021 (November 8, 2021): 57–65. http://dx.doi.org/10.18565/pharmateca.2021.11.57-65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Craciun, Doina, Edwin A. Laszlo, Julia C. Mirza-Rosca, et al. "Structural Parameters and Behavior in Simulated Body Fluid of High Entropy Alloy Thin Films." Materials 17, no. 5 (2024): 1162. http://dx.doi.org/10.3390/ma17051162.

Full text
Abstract:
The structure, composition and corrosion properties of thin films synthesized using the Pulsed Laser Deposition (PLD) technique starting from a three high entropy alloy (HEA) AlCoCrFeNix produced by vacuum arc remelting (VAR) method were investigated. The depositions were performed at room temperature on Si and mirror-like polished Ti substrates either under residual vacuum (low 10−7 mbar, films denoted HEA2, HEA6, and HEA10, which were grown from targets with Ni concentration molar ratio, x, equal to 0.4, 1.2, and 2.0, respectively) or under N2 (10−4 mbar, films denoted HEN2, HEN6, and HEN10
APA, Harvard, Vancouver, ISO, and other styles
10

Liberko, Marián, and Renata Soumarová. "Her2 positive metastatic gastric cancer." Onkologie 18, no. 4 (2024): 249–53. http://dx.doi.org/10.36290/xon.2024.051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "He52"

1

Waiz, Oliver [Verfasser], and Jan [Akademischer Betreuer] Harder. "Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom." Freiburg : Universität, 2012. http://d-nb.info/1123468273/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bender, Brendan. "Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-292617.

Full text
Abstract:
In oncology, there is a need to optimize drug treatment for efficient eradication of tumors, minimization of adverse effects (AEs), and prolonging patient survival. Pharmacometric models can be developed to streamline information between drug development phases, describe and quantify response to treatment, and determine dose regimens that balance toxicity and efficacy. In this thesis, data from trastuzumab emtansine (T-DM1) and taxane drug treatment were used to develop pharmacometric models of pharmacokinetics (PK), AEs, anti-tumor response, and survival, supporting drug development. T-DM1 is
APA, Harvard, Vancouver, ISO, and other styles
3

Aldana, Hidalgo Julio Xavier, Parodi Augusto José Amador, Palacios Jorge Martin Arredondo, et al. "Estrategias de redacción - HE59 201801." Universidad Peruana de Ciencias Aplicadas (UPC), 2018. http://hdl.handle.net/10757/624389.

Full text
Abstract:
Descripción: Estrategias de Redacción es un curso de Humanidades, que brinda al participante un conjunto de herramientas lingüísticas para la redacción en el entorno laboral, tales como el uso apropiado de la normativa del español y la aplicación de estrategias de redacción como la enumerativa y la causal. Estas últimas se emplean en la elaboración de un tipo de documento: el informe de recomendación. Propósito: El curso desarrolla la competencia de comunicación escrita en el primer nivel de logro. La asignatura se orienta a la redacción de textos administrativos que ayuden a optimizar el
APA, Harvard, Vancouver, ISO, and other styles
4

Li, Bob T. "Targeting HER2 in lung cancers." Thesis, University of Sydney, 2020. https://hdl.handle.net/2123/23996.

Full text
Abstract:
Therapeutic targeting of human epidermal growth factor receptor 2 (HER2) has transformed the care of women with breast cancers with substantial improvement in survival. In contrast, lung cancers remain the leading cause of cancer mortality, with over 1.7 million deaths annually worldwide. This research set out to test whether the therapeutic advances in targeting HER2 in breast cancers may be applied to lung cancers to improve outcomes. Translational research on lung tumour biospecimens from 175 patients found that HER2 mutations and HER2 amplification are two distinct therapeutic targets, eac
APA, Harvard, Vancouver, ISO, and other styles
5

(UPC), Universidad Peruana de Ciencias Aplicadas, and Celis Ingunza Sandy Cecilia. "Creatividad Y Liderazgo-HE50-201601." Universidad Peruana de Ciencias Aplicadas (UPC), 2016. http://hdl.handle.net/10757/639326.

Full text
Abstract:
Creatividad y Liderazgo es un curso de formación general de carácter teórico y práctico que está dirigido a estudiantes de quinto ciclo a más de las Facultades de negocios e Ingeniería y que desarrolla una de las competencias generales de nuestro modelo educativo: Pensamiento Innovador.El curso Creatividad y Liderazgo surge como una respuesta a los vertiginosos cambios tecnológicos y sociales que ocurren en nuestros días los que a su vez producen profundas transformaciones en la cultura corporativa de empresas e instituciones. Esto enfrenta a los ejecutivos a cada vez mayores exigencias profes
APA, Harvard, Vancouver, ISO, and other styles
6

(UPC), Universidad Peruana de Ciencias Aplicadas, and Garcia Soria Juddy Grethel Nora. "Creatividad Y Liderazgo-HE50-201602." Universidad Peruana de Ciencias Aplicadas (UPC), 2016. http://hdl.handle.net/10757/639327.

Full text
Abstract:
Creatividad y Liderazgo es un curso de formación general de carácter teórico y práctico que está dirigido a estudiantes de quinto ciclo a más de las Facultades de negocios e Ingeniería y que desarrolla una de las competencias generales de nuestro modelo educativo: Pensamiento Innovador.El curso Creatividad y Liderazgo surge como una respuesta a los vertiginosos cambios tecnológicos y sociales que ocurren en nuestros días los que a su vez producen profundas transformaciones en la cultura corporativa de empresas e instituciones. Esto enfrenta a los ejecutivos a cada vez mayores exigencias profes
APA, Harvard, Vancouver, ISO, and other styles
7

(UPC), Universidad Peruana de Ciencias Aplicadas, and Ilizarbe Jurado Anndy Antonio. "Creatividad Y Liderazgo-HE50-201701." Universidad Peruana de Ciencias Aplicadas (UPC), 2017. http://hdl.handle.net/10757/639328.

Full text
Abstract:
Creatividad y Liderazgo es un curso de formación general de carácter teórico y práctico que está dirigido a estudiantes de quinto ciclo a más de las Facultades de Negocios e Ingeniería y busca desarrollar una de las competencias generales de nuestro modelo educativo: Pensamiento Innovador.El curso Creatividad y Liderazgo surge como una respuesta a la necesidad de profesionales que cuenten con estrategias y metodologías para afrontar los vertiginosos cambios que ocurren en nuestros días los que a su vez producen profundas transformaciones en la cultura corporativa de empresas e instituciones. E
APA, Harvard, Vancouver, ISO, and other styles
8

Collins, Bridget. "Vaccination with Her2/neu peptides elicits an endogenous anti-Her2/neu antibody response in mice." [New Haven, Conn. : s.n.], 2007. http://ymtdl.med.yale.edu/theses/available/etd-08062007-143035/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vicario, Rocío. "Immunotherapy against HER2-positive breast cancers." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/400279.

Full text
Abstract:
El 20% de los tumores mamarios sobre expresan el receptor de tirosina quinasa HER2, debido a su amplificación génica, tanto dentro de los cromosomas (HSR) como fuera ellos (DM). Se sabe muy poco acerca de la respuesta clínica o el rol en resistencia a terapias de estos patrones de amplificación. Por otro lado, un porcentaje de pacientes HER2+ expresa fragmentos carboxyl-terminales de HER2, p95HER2. Mas de la mitad de pacientes HER2+ no responde a las terapias disponibles. Hasta el momento, se desconoce si p95HER2 puede ser un blanco terapéutico. En este trabajo estudiaremos resistencia
APA, Harvard, Vancouver, ISO, and other styles
10

Maslak, Kerstin [Verfasser]. "Untersuchung zur synergistischen Wirkung von Lapatinib (GW 2016), einem potenten dualen HER1-HER2-Tyrosinkinaseinhibitor, und Fulvestrant, einem Östrogenrezeptorantagonisten, in HER2 und nicht HER2 überexprimierenden Brustkrebszellen / Kerstin Maslak." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2012. http://d-nb.info/1030290946/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "He52"

1

Shockney, Lillie. Top concerns about HER2 positive breast cancer. Jones & Bartlett Learning, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alvarez, Ricardo H., Javier Cortés, Mary Falzon, et al. Handbook of HER2-Targeted Agents in Breast Cancer. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28216-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alvarez, Ricardo H., Javier Cortés, Leticia De Mattos-Arruda, et al. Handbook of HER2-targeted agents in breast cancer. Springer Healthcare Ltd., 2013. http://dx.doi.org/10.1007/978-1-907673-94-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Williams, Sophie I., and Christopher E. Rogers. HER2 and cancer: Mechanism, testing, and targeted therapy. Nova Biomedical Books, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stärk, Dagmar. Theoretische Untersuchung der Ladungsaustauschreaktionen in den Systemen ArN2+ [ArN] und HeN2+ [HeN]. [s.n.], 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kay, Bartholomew L., ed. Planning health promotion programs: An intervention mapping approach. Jossey-Bass, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schulzke, Sven Michael. Immunhistochemische Charakterisierung von humanen Tumorxenografts auf die Expression von EGFR, TGF[alpha] [TGFalpha], EGF und p185[superscript HER2]. [s.n.], 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Oehlrich, Marcus. Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene: A systematic review. dissertation.de, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

cai, Jin sheng. Ping di ke ^wei guan jing ji xue~ (di4 he5 ban) bi ji he ke hou xi ti xiang jie. Zhong guo shi hua chu ban she, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mastering Autodesk Revit Architecture 2014: Autodesk Official Press. Wiley & Sons, Incorporated, John, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "He52"

1

Zhu, Hua, Xiaoyi Guo, Xiangxi Meng, and Zhi Yang. "Is It Possible to Target HER2 Using Affibody Receptor Radionuclide Therapy?" In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_38.

Full text
Abstract:
AbstractHuman epidermal receptor type 2 (HER2; also known as ErbB2) is an idea target for target therapy. HER2-targeted treatments with trastuzumab and its derivates or analogues can improve the overall survival of patients with HER2-overexpression tumors. This chapter describes the construction and clinical translational study of 64Cu-NOTA-Trastuzumab, 124I-Trastuzumab, and 68Ga-HER2 affibody tracer. Inspired by recently most popular peptide receptor radionuclide therapy with lutetium-177 dotatate (177Lu-DOTATATE) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and 177Lu-
APA, Harvard, Vancouver, ISO, and other styles
2

Disis, Mary L., and Megan M. O’Meara. "HER2/neu." In Cancer Therapeutic Targets. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-0717-2_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ross, Jeffrey S., and Jonathan A. Fletcher. "HER2/neu." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_2677-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Disis, Mary L., and Megan M. O’Meara. "HER2/neu." In Cancer Therapeutic Targets. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6613-0_46-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ross, Jeffrey S., and Jonathan A. Fletcher. "HER2/neu." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_2677.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Falzon, Mary, and Michael Gandy. "HER2 testing." In Handbook of HER2-Targeted Agents in Breast Cancer. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28216-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Falzon, Mary, and Michael Gandy. "HER2 Testing." In Handbook of HER2-targeted agents in breast cancer. Springer Healthcare Ltd., 2013. http://dx.doi.org/10.1007/978-1-907673-94-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dinh, Phuong, Gianluca Tomasello, and Martine J. Piccart. "HER2-Targeted Therapy." In Management of Breast Diseases. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-69743-5_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Beuzeboc, P., S. Scholl, and J. Gligorov. "Anticorps anti-HER2." In Les thérapies ciblées. Springer Paris, 2008. http://dx.doi.org/10.1007/978-2-287-36008-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dinh, Phuong, and Martine J. Piccart. "HER2-Targeted Therapy." In Management of Breast Diseases. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46356-8_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "He52"

1

Selcuk, Sahan Yoruc, Xilin Yang, Bijie Bai, et al. "Deep Learning-Enabled Classification of HER2 Score in Breast Cancer Using Pyramid Sampling." In CLEO: Applications and Technology. Optica Publishing Group, 2024. http://dx.doi.org/10.1364/cleo_at.2024.ath1b.7.

Full text
Abstract:
We present an automated, deep learning-based method for HER2 score classification in breast cancer, achieving 85.47% accuracy on tissue microarrays from 300 patients. This method can significantly improve the HER2 evaluation process, saving diagnostician time.
APA, Harvard, Vancouver, ISO, and other styles
2

Toledo, Fernanda José de, Victor Domingos Lisita Rosa, Augusto Rodrigues de Araujo Neto, et al. "Evaluation of HER2-low incidence in the clinical oncology service of Hospital das Clínicas da Universidade Federal de Goiás." In Brazilian Breast Cancer Symposium 2024. Mastology, 2024. http://dx.doi.org/10.29289/259453942024v34s1070.

Full text
Abstract:
Objective: The objective of this study was to determine the incidence and epidemiology of patients with Human Epidermal Growth Factor Receptor-type 2 (HER2-low) breast cancer in the oncology service of the HC-UFG from March 2022 to February 2023. Methodology: This is an observational and cross-sectional study, which included patients diagnosed with invasive breast cancer and excluded those with immunohistochemistry HER2 3+, HER2 0, or HER2 2+ with positive fluorescent in situ hybridization (FISH) by immunohistochemistry and those under 18 years old. Results: HER2-low tumors at HC-UFG are predo
APA, Harvard, Vancouver, ISO, and other styles
3

Neto, Eclésio Batista De Oliveira, Esther Mendonça Dos Santos, Daiane Maria Correia De Souza Guimarães, and Rubens Cleiton Andrade Santana. "O USO DO TRASTUZUMABE DERUXTECAN NO TRATAMENTO DO CÂNCER DE MAMA HER2+ EM PACIENTES COM METÁSTASES CEREBRAIS." In I Congresso Brasileiro On-line de Ensino, Pesquisa e Extensão. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ensipex/52.

Full text
Abstract:
Introdução: O câncer de mama HER2+ é um câncer de mama com teste positivo para uma proteína chamada de human epidermal growth factor receptor 2 (HER2), em português: receptor do fator de crescimento epidérmico humano 2. Esta proteína atua no crescimento celular normal, no entanto, é encontrada em alguns tipos de células cancerígenas, presentes no câncer de mama e ovário. As células neoplásicas com a presença de HER2, frequentemente apresentam cópias extras do gene HER2, e superprodução desses receptores. O resultado é uma hiper sinalização, que favorece o desenvolvimento dos tumores. Os câncer
APA, Harvard, Vancouver, ISO, and other styles
4

Yoshimura, Adriana Akemi, André Mattar, Bruna S. Mota, et al. "A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: II – HISTOPATHOLOGIC AND MOLECULAR DATA." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1062.

Full text
Abstract:
Introduction: Ultra young women (UYW) is defined as women aged up to 30 years. UYW with BC share some unfavorable biological tumor characteristics as larger size at diagnosis, higher loca-regional recurrence rate and lower survival, and have been merited specialized care. Objectives: We aimed to determine histopathological and molecular characteristics of BC in UYW. Methods: We carried out a multicentric, observational, retrospective study of consecutive UYW patients with BC. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo took part in
APA, Harvard, Vancouver, ISO, and other styles
5

Gomes Filho, José Euderaldo Costa, Gisele Aparecida Fernandes, Rossana Verónica Mendoza López, and Maria Paula Curado. "IMMUNOPHENOTYPING OF BREAST CANCER ASSOCIATED WITH MALIGNANT TUMOR CLASSIFICATION AND HISTOPATHOLOGICAL FEATURES." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2057.

Full text
Abstract:
Objective: The immunohistochemical profile of breast cancer is based on the evaluation of estrogen and progesterone receptors, HER2 expression, and cell proliferation index. An investigation of the association of immunophenotyping with the classification of tumors and the description of their anatomical extent becomes important in view of the scarcity of research in mixed populations such as the Brazilian. Thus, this research performed the association of immunophenotyping — luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-positive, and triple-negative — with the classification
APA, Harvard, Vancouver, ISO, and other styles
6

Barbalho, Caio Henrique Silveira, ECLÉSIO BATISTA DE OLIVEIRA NETO, ESTHER MENDONÇA DOS SANTOS, and DAIANE MARIA CORREIA DE SOUZA GUIMARÃES. "USO DA IMUNOTERAPIA NO TRATAMENTO DO CÂNCER DE MAMA HER2+." In II Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conbrai/6360.

Full text
Abstract:
Introdução: Algumas neoplasias malignas de mama expressam a proteína HER2. Estes são denominados câncer de mama HER2+, esta proteína está envolvida com a proliferação celular. Esses cânceres geralmente crescem e se espalham rápido, no entanto, respondem melhor ao tratamento com fármacos que têm como escopo a proteína HER2. Trastuzumab deruxtecan é um anticorpo conjugado direcionado às neoplasias malignas HER2-positivas, atua sobre os tumores que expressam a HER2, inibindo a topoisomerase I do DNA. Este fármaco vem se mostrando eficaz no tratamento do câncer de mama que expressa HER2. Objetivo:
APA, Harvard, Vancouver, ISO, and other styles
7

Bai, Bijie, Hongda Wang, Yuzhu Li, et al. "Deep Learning-based Virtual Immunohistochemical HER2 staining of Label-Free Breast Tissue." In CLEO: Science and Innovations. Optica Publishing Group, 2022. http://dx.doi.org/10.1364/cleo_si.2022.sm5o.2.

Full text
Abstract:
We present deep learning-based virtual immunohistochemical (IHC) HER2 staining of label-free breast tissue sections, matching the standard IHC HER2 staining performed by histotechnologists. © 2022 The Author(s)
APA, Harvard, Vancouver, ISO, and other styles
8

Lobry, Maxime, Médéric Loyez, Marc Debliquy, Karima Chah, Erik Goormaghtigh, and Christophe Caucheteur. "Electro-plasmonic cancer biomarkers sensing using fiber Bragg gratings." In Bragg Gratings, Photosensitivity and Poling in Glass Waveguides and Materials. Optica Publishing Group, 2022. http://dx.doi.org/10.1364/bgppm.2022.bth1a.5.

Full text
Abstract:
An electro-plasmonic optical fiber grating biosensor was designed to attract and specifically detect breast cancer biomarkers (HER2) using aptamers. The developed biosensor exhibits a high sensitivity with an enhanced limit of detection to HER2.
APA, Harvard, Vancouver, ISO, and other styles
9

Шешукова, Е. В., К. А. Камарова, Н. М. Ершова, and Т. В. Комарова. "MODIFICATION OF THE AMINO ACID SEQUENCE OF THE FC FRAGMENT OF THE ANTIBODY DIRECTED AGAINST THE HER2/NEU ONCOPROTEIN AND PRODUCED IN PLANTS." In Биотехнология в растениеводстве, животноводстве и сельскохозяйственной микробиологии. Crossref, 2022. http://dx.doi.org/10.48397/arriab.2022.22.xxii.032.

Full text
Abstract:
Развитие биотехнологии в последние десятилетия позволило рассматривать растение как «фабрику» для получения рекомбинантных белков. Благодаря высокому уровню синтеза в растительной клетке и относительной простоте очистки антитела являются одним из перспективных объектов для продукции в растении. В настоящее время существует около сотни терапевтических моноклональных антител, применяемых в терапии различных заболеваний [1], в том числе HER2/neu-позитивного рака молочной железы. HER2/neu принадлежит к семейству рецепторов эпидермального фактора роста человека. The development of biotechnology in
APA, Harvard, Vancouver, ISO, and other styles
10

Pimentel, Franklin Fernandes, Daniel Guimarães Tiezzi, Jurandyr Moreira de Andrade, et al. "SYNERGISTIC MECHANISMS OF ACTION: COMPARISON OF ADCC AND SIGNALING PATHWAYS INHIBITION BY TRASTUZUMAB BIOSIMILAR OR ORIGINATOR TRASTUZUMAB IN COMBINATION WITH PERTUZUMAB IN HER2+ BREAST CANCER CELL LINES." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2009.

Full text
Abstract:
Objectives: Trastuzumab and pertuzumab bind to HER2 synergistically at different subdomains, improving the clinical benefit of breast cancer treatment. Recently, trastuzumab biosimilars were approved after comparison with the originator, proving high similarity in structure and activity, and equivalent efficacy, safety, and immunogenicity. This study aimed to compare in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) and HER2-signaling inhibition elicited by biosimilar trastuzumab (BS-TZB) or originator trastuzumab (TZB) in combination with pertuzumab (PTZ). Methodology: Human breas
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "He52"

1

Ballestas Baena, Alanys, Walter Cardona Silgado, Andres Cassiani Herazo, Emmanuel Salgado Rodriguez, Jose Rincon Jaime, and Ariel Pastrana Arias (director). Evaluación experimental de la curcumina en cáncer de mama. Universidad de Cartagena, 2024. https://doi.org/10.32997/11227/18490.

Full text
Abstract:
La investigacion basica de la curcumina en modelos celulares de cancer de mama MCF7/LCC9 muestra su eficacia para disminuir la proliferacion celular. Ademas, la evidencia mostrada indica que la asociacion de curcumina mas tamoxifeno podria reducir la resistencia farmacologica a este ultimo. Todo lo anterior tomado en conjunto indica el potencial terapéutico en el cáncer de mama TNBC. La incidencia del cáncer de mama (CM) ha ido en aumento, convirtiéndose en la quinta causa de muerte asociada al cáncer. El CM se asocia con cuatro biomarcadores significativos: receptor de estrógenos (ER), recept
APA, Harvard, Vancouver, ISO, and other styles
2

Lai, Vy P. CD4+ Th1 HER2-Specific T Cells as a Novel Treatment for HER2-Overexpresssing Breast Cancer. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada499837.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lai, Vy P. CD4+ Th1 HER2-Specific T Cells as a Novel Treatment for HER2-Overexpressing Breast Cancer. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada477515.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Surmacz, Eva. HER2/Leptin Crosstalk in Breast Cancer. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada493685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Surmacz, Eva. HER2/Leptin Crosstalk in Breast Cancer. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada516501.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sherman, Michael. Hsf1 in Her2-Positive Breast Cancer. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada571331.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gill, Parkash, Debasish Tripathy, and Debra Hawes. Co-Targeting HER2 and EphB4 Pathways. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada573435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Geballe, Adam. Translational Regulation of HER2 Gene Expression. Defense Technical Information Center, 1997. http://dx.doi.org/10.21236/ada339298.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sherman, Michael. Hsf1 in Her2-positive Breast Cancer. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada558808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Knutson, Keith L., and Mary Disis. Ex Vivo Expansion of HER2-Specific T Cells for the Treatment of HER2-Overexpressing Breast Cancer. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada416629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'He52' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography